Dr Niikura on T-DXd in Patients With HER2+ Breast Cancer With Brain Metastases and Leptomeningeal Disease
Naoki Niikura, MD, PhD, discusses the impact of treatment with trastuzumab deruxtecan in patients with HER2-positive breast cancer with brain metastases and/or leptomeningeal disease, as evaluated in the real-world ROSET-BM study in Japan.
Naoki Niikura Tokai University School Of Medicine Department Of Breast Oncology National Comprehensive Cancer Network Breast Oncology Tokai University School
Source: onclive.com